Patents-Review.com
ClassID:

21165 ⎘

A61K2039/5156 - page 2 - CPC Classification

Classification description:

Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA; Animal cells expressing foreign proteins

Recent Application in this class:
#301
20220168345
2022-06-02

T CELL RECEPTORS AND METHODS OF USE THEREOF

 #302
20220162554
2022-05-26

MODIFIED T CELLS AND METHODS OF MAKING AND USING THE SAME

 #303
20220162340
2022-05-26

Compositions and methods for immunotherapy

 #304
20220160852
2022-05-26

HUMAN VACCINE COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA

 #305
20220154191
2022-05-19

ENHANCEMENT OF CYTOLYTIC T-CELL ACTIVITY BY INHIBITING EBAG9

 #306
20220154190
2022-05-19

Altering Gene Expression in Modified T Cells and Uses Thereof

 #307
20220152169
2022-05-19

COLORECTAL CANCER TUMOR CELL VACCINES

 #308
20220145306
2022-05-12

Altering Gene Expression in Modified T Cells and Uses Thereof

 #309
20220145251
2022-05-12

GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE

 #310
20220135945
2022-05-05

GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE

 #311
20220135699
2022-05-05

CHIMERIC ANTIGEN RECEPTOR COMPRISING INTERLEUKIN-15 INTRACELLULAR DOMAIN AND USES THEREOF

 #312
20220133797
2022-05-05

Notch receptors with hinge domain

 #313
20220127570
2022-04-28

IMMUNE EFFECTOR CELL AND USE THEREOF

 #314
20220127329
2022-04-28

ALTERNATIVE INTRACELLULAR SIGNALLING DOMAIN OF A CHIMERIC ANTIGEN RECEPTOR

 #315
20220125905
2022-04-28

MESOTHELIN CARS AND USES THEREOF

 #316
20220125836
2022-04-28

TREATMENT INVOLVING CAR-ENGINEERED T CELLS AND CYTOKINES

 #317
20220106370
2022-04-07

VARIANT SURVIVIN VACCINE FOR TREATMENT OF CANCER

 #318
20220105166
2022-04-07

ANUCLEATE CELL-DERIVED VACCINES

 #319
20220098297
2022-03-31

Bispecific antibody specifically binding to IL-17A and TNF-α

 #320
20220098273
2022-03-31

Chimeric engulfment receptor molecules

 #321
20220096615
2022-03-31

COMPOSITIONS AND METHODS FOR TREATING IMMUNOLOGICAL DYSFUNCTION

 #322
20220088190
2022-03-24

Compositions and Methods for Targeting Mutant RAS

 #323
20220088163
2022-03-24

Hybrid immolative cell-penetrating complexes for nucleic acid delivery

 #324
20220073639
2022-03-10

Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias

 #325
20220073585
2022-03-10

CHIMERIC ANTIGEN RECEPTOR MEMORY-LIKE (CARML) NK CELLS AND METHODS OF MAKING AND USING SAME

 #326
20220072041
2022-03-10

GENE MODIFIED IMMUNE EFFECTOR CELLS AND ENGINEERED CELLS FOR EXPANSION OF IMMUNE EFFECTOR CELLS

 #327
20220064305
2022-03-03

T cell modification and use thereof

 #328
20220064292
2022-03-03

Drug regulated transgene expression

 #329
20220062343
2022-03-03

GENETICALLY MODIFIED NK-92 CELLS HAVING A SAFETY SWITCH

 #330
20220056409
2022-02-24

T-CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS

 #331
20220056139
2022-02-24

Lym-1 and Lym-2 antibody compositions and improved car constructs

 #332
20220056105
2022-02-24

D-domain containing polypeptides and uses thereof

 #333
20220054608
2022-02-24

ANTIGEN-SPECIFIC T CELLS FOR INDUCING IMMUNE TOLERANCE

 #334
20220050114
2022-02-17

METHODS FOR MASS SPECTROMETRY ANALYSIS OF ENGINEERED CELL COMPOSITIONS

 #335
20220047635
2022-02-17

METHODS FOR THE SIMULTANEOUS EXPANSION OF MULTIPLE IMMUNE CELL TYPES, RELATED COMPOSITIONS AND USES OF SAME IN CANCER IMMUNOTHERAPY

 #336
20220041688
2022-02-10

Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof

 #337
20220033468
2022-02-03

Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof

 #338
20220033466
2022-02-03

Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof

 #339
20220033462
2022-02-03

INHIBITORY CHIMERIC ANTIGEN RECEPTORS

 #340
20220033461
2022-02-03

ANTIGEN RECEPTORS AND USES THEREOF

 #341
20220031822
2022-02-03

CHIMERIC ANTIGEN RECEPTORS COMPRISING BCMA-SPECIFIC FIBRONECTIN TYPE III DOMAINS AND USES THEREOF

 #342
20220023344
2022-01-27

ALLOGENEIC CELL THERAPY OF ACUTE LYMPHOBLASTIC LEUKEMIA USING GENETICALLY ENGINEERED T CELLS TARGETING CD19

 #343
20220023338
2022-01-27

COMPOSITIONS AND METHODS RELATED TO TUMOR CELL KILLERS AND VACCINES

 #344
20220018845
2022-01-20

Articles and methods directed to personalized therapy of cancer

 #345
20220016170
2022-01-20

CONSTITUTIVE EXPRESSION OF COSTIMULATORY LIGANDS ON ADOPTIVELY TRANSFERRED T LYMPHOCYTES

 #346
20220008526
2022-01-13

METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY

 #347
20220008522
2022-01-13

Immunosuppressive antigen-specific chimeric antigen receptor Treg cells for prevention and/or treatment of autoimmune and alloimmune disorders

 #348
20220008473
2022-01-13

USE OF CHIMERIC ANTIGEN RECEPTOR T CELLS AND NK CELL INHIBITORS FOR TREATING CANCER

 #349
20220008472
2022-01-13

Immunotherapy with B*08 restricted peptides and combination of peptides against cancers and related methods

 #350
20220008469
2022-01-13

Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

 #351
20220008465
2022-01-13

METHODS OF DOSING ENGINEERED T CELLS FOR THE TREATMENT OF B CELL MALIGNANCIES

 #352
20220002675
2022-01-06

Constructs for chimeric antigen receptors

 #353
20220002377
2022-01-06

Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof

 #354
20220002376
2022-01-06

Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof

 #355
20220002375
2022-01-06

Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof

 #356
20220000996
2022-01-06

Chimeric antigen receptor-expressing T cells as anti-cancer therapeutics

 #357
20220000925
2022-01-06

Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

 #358
20220000924
2022-01-06

Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

 #359
20220000923
2022-01-06

Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

 #360
20220000922
2022-01-06

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #361
20220000918
2022-01-06

Method of increasing tumor killing activity of macrophages or monocytes comprising chimeric antigen receptor

 #362
20210403952
2021-12-30

METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF

 #363
20210403885
2021-12-30

CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY

 #364
20210403517
2021-12-30

D-domain containing polypeptides and uses thereof

 #365
20210401980
2021-12-30

Immunotherapy method comprising administering a combination of immune effector cells and non-target hematopoietic cells

 #366
20210401955
2021-12-30

CD4 T cells provide antibody access to immunoprivileged tissue

 #367
20210401892
2021-12-30

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #368
20210401891
2021-12-30

D-domain containing polypeptides and uses thereof

 #369
20210401887
2021-12-30

T CELLS FROM LYMPHATIC FLUID FOR DIAGNOSTIC AND THERAPEUTIC USE

 #370
20210395362
2021-12-23

CAR-T cells with humanized CD19 ScFv with mutation in CDR 1 region

 #371
20210393753
2021-12-23

FGL2 NEUTRALING CELL THERAPY AND METHODS OF USE THEREOF

 #372
20210393694
2021-12-23

Coordinating gene expression using RNA destabilizing elements

 #373
20210393688
2021-12-23

MODIFIED PDC LINE FOR SECRETING A CYTOKINE

 #374
20210388113
2021-12-16

Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer

 #375
20210386840
2021-12-16

BI-SPECIFIC TARGETED CHIMERIC ANTIGEN RECEPTOR T CELLS

 #376
20210379111
2021-12-09

Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

 #377
20210371540
2021-12-02

Chimeric antigen receptors with mutated CD28 phosphorylation sites

 #378
20210371517
2021-12-02

METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY

 #379
20210371515
2021-12-02

Immunocytes expressing a chimeric antigen receptor binding to cancer cells and TNF-related apoptosis-inducing ligand (trail)

 #380
20210369774
2021-12-02

MICRO-RNA-155 ENHANCES THE EFFICACY OF DENDRITIC CELL VACCINE FOR CANCER

 #381
20210363258
2021-11-25

HPV-SPECIFIC BINDING MOLECULES

 #382
20210363212
2021-11-25

GENETICALLY ENGINEERED CAR T CELLS THAT SECRET INTERLEUKIN-12 AND THERAPEUTIC USES THEREOF

 #383
20210361713
2021-11-25

Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

 #384
20210361712
2021-11-25

Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

 #385
20210361710
2021-11-25

Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof

 #386
20210353677
2021-11-18

Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

 #387
20210348166
2021-11-11

IMMUNOTHERAPY OF CANCER

 #388
20210347913
2021-11-11

Masked chimeric antigen receptor specific to tyrosine-protein kinase like 7 (PTK7) and immune cells expressing such

 #389
20210347850
2021-11-11

Fc-epsilon car

 #390
20210346477
2021-11-11

COSTIMULATION OF CHIMERIC ANTIGEN RECEPTORS BY MYD88 AND CD40 POLYPEPTIDES

 #391
20210338814
2021-11-04

COMBINATION OF IMMUNE EFFECTOR CELLS SPECIFIC FOR A TARGET ANTIGEN AND HEMATOPOIETIC CELLS THAT EXPRESS THE TARGET ANTIGEN IN AN ALTERED FORM

 #392
20210338735
2021-11-04

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #393
20210338734
2021-11-04

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #394
20210338727
2021-11-04

NATURAL KILLER CELL COMPOSITIONS AND IMMUNOTHERAPY METHODS FOR TREATING TUMORS

 #395
20210338726
2021-11-04

ENGINEERED REGULATORY T CELL

 #396
20210333282
2021-10-28

ARTICLES AND METHODS DIRECTED TO PERSONALIZED THERAPY OF CANCER

 #397
20210330783
2021-10-28

HIV pre-immunization and immunotherapy

 #398
20210330770
2021-10-28

Use of car and bite technology coupled with an SCFV from an antibody against human thymidine kinase 1 to specifically target tumors

 #399
20210330769
2021-10-28

Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer

 #400
20210330708
2021-10-28

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #401
20210317409
2021-10-14

METHODS, KITS, AND COMPOSITIONS FOR ENHANCING CELLULAR THERAPY

 #402
20210317407
2021-10-14

METHODS AND COMPOSITIONS FOR STIMULATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS WITH HAPTEN LABELLED CELLS

 #403
20210315985
2021-10-14

Chimeric antigen receptor (CAR) that targets chemokine receptor CCR4 and its use

 #404
20210309758
2021-10-07

Antibodies to MUC16 and methods of use thereof

 #405
20210308261
2021-10-07

EGFR-DIRECTED CAR THERAPY FOR GLIOBLASTOMA

 #406
20210301024
2021-09-30

COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY TARGETING FLT3, PD-1, AND/OR PD-L1

 #407
20210299280
2021-09-30

Compositions and methods for transient gene therapy with enhanced stability

 #408
20210299246
2021-09-30

METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT OF VIRAL OR VIRALLY-INDUCED INFECTIONS AND CONDITIONS, AND ANTI-VIRAL COMPOSITIONS AND THEIR PRODUCTION

 #409
20210292429
2021-09-23

ANTI-LIV1 IMMUNE CELL CANCER THERAPY

 #410
20210292427
2021-09-23

METHOD FOR TREATING TUMOR USING IMMUNE EFFECTOR CELL

 #411
20210292389
2021-09-23

NEW CAR CONSTRUCTS COMPRISING TNFR2 DOMAINS

 #412
20210290750
2021-09-23

Vectors and vaccine cells for immunity against Zika virus

 #413
20210290679
2021-09-23

Coordinating Gene Expression Using RNA Destabilizing Elements

 #414
20210283180
2021-09-16

CAR T CELL THERAPY TO TARGET T CELL SPECIFIC CANCERS

 #415
20210269537
2021-09-02

Anti-mesothelin chimeric antigen receptor (CAR) constructs and uses thereof

 #416
20210269500
2021-09-02

Cell surface coupling of nanoparticles

 #417
20210268024
2021-09-02

Notch receptors with hinge domain

 #418
20210261919
2021-08-26

Methods and compositions for treating cancer

 #419
20210260120
2021-08-26

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #420
20210254003
2021-08-19

CAR-T LYMPHOCYTES ENGINEERED TO HOME TO LYMPH NODE B CELL ZONE, SKIN, OR GASTROINTESTINAL TRACT

 #421
20210253729
2021-08-19

ENHANCED CHIMERIC ANTIGEN RECEPTORS AND USE THEREOF

 #422
20210253707
2021-08-19

GM-CSF/CD40L VACCINE AND CHECKPOINT INHIBITOR COMBINATION THERAPY

 #423
20210252084
2021-08-19

Adoptive cellular therapy

 #424
20210252060
2021-08-19

Materials and methods for engineering cells and uses thereof in immuno-oncology

 #425
20210246425
2021-08-12

Methods and compositions for treating cancer

 #426
20210246215
2021-08-12

EphA3 directed CAR-T cells for treatment of tumors

 #427
20210244765
2021-08-12

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #428
20210236613
2021-08-05

Combined formulation comprising four linked cytotoxic T lymphocyte (CTL) epitopes and a PD-1 pathway inhibitor and methods of use thereof to treat cancer

 #429
20210236610
2021-08-05

ALLOGENEIC TUMOR CELL VACCINE

 #430
20210236552
2021-08-05

Materials and methods for engineering cells and uses thereof in immuno-oncology

 #431
20210236551
2021-08-05

Materials and methods for engineering cells and uses thereof in immuno-oncology

 #432
20210236550
2021-08-05

Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer

 #433
20210230251
2021-07-29

UNIVERSAL PLATFORM FOR CAR THERAPY TARGETING A NOVEL ANTIGENIC SIGNATURE OF CANCER

 #434
20210230241
2021-07-29

MODIFIED NATURAL KILLER CELLS AND NATURAL KILLER CELL LINES HAVING INCREASED CYTOTOXICITY

 #435
20210221880
2021-07-22

Chimeric antigen receptor and application thereof

 #436
20210220403
2021-07-22

TARGETING THE TUMOR MICROENVIRONMENT USING MANIPULATED NKT CELLS

 #437
20210214415
2021-07-15

IMMUNORESPONSIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF

 #438
20210213064
2021-07-15

Peptides and combination of peptides of non- canonical origin for use in immunotherapy against different types of cancers

 #439
20210207093
2021-07-08

Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

 #440
20210205361
2021-07-08

COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY

 #441
20210190763
2021-06-24

QUALITY OF IMMUNOLOGICAL SYNAPSE PREDICTS EFFECTIVENESS OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS

 #442
20210189338
2021-06-24

Method of manufacturing dual specific T-cells for use in cancer immunotherapy

 #443
20210187018
2021-06-24

CYTOBIOLOGICS AND THERAPEUTIC USES THEREOF

 #444
20210179733
2021-06-17

Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same

 #445
20210179723
2021-06-17

Human CGRP receptor binding proteins

 #446
20210177953
2021-06-17

Engineered Non-Human Derived Immune Cells for Universal Adoptive Antigen Cellular Immunotherapy

 #447
20210177951
2021-06-17

ENGINEERED CELLS & METHODS

 #448
20210177899
2021-06-17

Genome editing of graft-derived T-cells for post-transplant immunotherapy

 #449
20210170025
2021-06-10

GP96-BASED CANCER THERAPY

 #450
20210170001
2021-06-10

CS1 targeted chimeric antigen receptor-modified T cells

 #451
20210162036
2021-06-03

Diluent for cell-associated alphaherpesvirus vaccine

 #452
20210162031
2021-06-03

Methods and compositions for treating cancers

 #453
20210147569
2021-05-20

Compositions and methods for CD20 immunotherapy

 #454
20210145888
2021-05-20

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #455
20210145887
2021-05-20

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #456
20210145886
2021-05-20

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #457
20210139583
2021-05-13

Production of engineered T-cells by sleeping beauty transposon coupled with methotrexate selection

 #458
20210138051
2021-05-13

Modified Natural Killer Cells and Natural Killer Cell Lines Having Increased Cytotoxicity

 #459
20210137986
2021-05-13

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #460
20210137985
2021-05-13

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #461
20210128625
2021-05-06

Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

 #462
20210128623
2021-05-06

PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY

 #463
20210113619
2021-04-22

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #464
20210113617
2021-04-22

METHODS AND COMPOSITIONS FOR TH9 CELL MEDIATED CANCER TREATMENT

 #465
20210113507
2021-04-22

Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy

 #466
20210113506
2021-04-22

Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy

 #467
20210108174
2021-04-15

Materials and methods for engineering cells and uses thereof in immuno-oncology

 #468
20210107996
2021-04-15

PLAP-CAR-effector cells

 #469
20210106622
2021-04-15

TARGETING THE TUMOR MICROENVIRONMENT USING MANIPULATED NKT CELLS

 #470
20210100845
2021-04-08

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #471
20210100842
2021-04-08

PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY

 #472
20210095010
2021-04-01

Compositions and methods for modified b cells expressing reassigned biological agents

 #473
20210087279
2021-03-25

REGULATABLE CHIMERIC ANTIGEN RECEPTOR

 #474
20210087249
2021-03-25

ANTIBODY-INTERFERON FUSION PROTEINS FOR ENHANCING ADOPTIVE T CELL THERAPIES FOR THE TREATMENT OF CANCER

 #475
20210085718
2021-03-25

Materials and methods for engineering cells and uses thereof in immuno-oncology

 #476
20210079349
2021-03-18

Reducing immune tolerance induced by PD-L1

 #477
20210079348
2021-03-18

Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

 #478
20210079059
2021-03-18

Treatment of cancer using GFR alpha-4 chimeric antigen receptor

 #479
20210077604
2021-03-18

BCMA chimeric antigen receptors

 #480
20210077603
2021-03-18

BCMA chimeric antigen receptors

 #481
20210077602
2021-03-18

COMPOSITION AND THERAPEUTIC ANTI-TUMOUR VACCINE

 #482
20210077565
2021-03-18

Method of treating a philadelphia chromosome-positive tumor

 #483
20210070864
2021-03-11

HLA-G AS A NOVEL TARGET FOR CAR T-CELL IMMUNOTHERAPY

 #484
20210069251
2021-03-11

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #485
20210069243
2021-03-11

Biologically relevant orthogonal cytokine/receptor pairs

 #486
20210060078
2021-03-04

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #487
20210060077
2021-03-04

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #488
20210060074
2021-03-04

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #489
20210060068
2021-03-04

BIOLOGICALLY RELEVANT ORTHOGONAL CYTOKINE/RECEPTOR PAIRS

 #490
20210054337
2021-02-25

Modified NK-92 cells for treating cancer

 #491
20210052711
2021-02-25

BCMA chimeric antigen receptors

 #492
20210052654
2021-02-25

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #493
20210052653
2021-02-25

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #494
20210052652
2021-02-25

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #495
20210052651
2021-02-25

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #496
20210046118
2021-02-18

ENGINEERED NATURAL KILLER CELLS AND USES THEREOF

 #497
20210046112
2021-02-18

Methods for Enhancing Efficacy of Therapeutic Immune Cells

 #498
20210038705
2021-02-11

BCMA chimeric antigen receptors

 #499
20210030860
2021-02-04

Self-antigen specific T-cells as vaccines for augmenting engraftment and stability of autologous transfer

 #500
20210030858
2021-02-04

METHODS AND MATERIALS FOR TREATING CANCER

 #501
20210030856
2021-02-04

CANCER IMMUNIZATION PLATFORM

 #502
20210030798
2021-02-04

CHIMERIC RECEPTOR

 #503
20210023189
2021-01-28

Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)

 #504
20210008189
2021-01-14

Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)

 #505
20210002377
2021-01-07

Treatment of cancer using a CD123 chimeric antigen receptor

 #506
20210002364
2021-01-07

Transgene genetic tags and methods of use

 #507
20210000945
2021-01-07

VECTOR CO-EXPRESSING VACCINE AND COSTIMULATORY MOLECULES

 #508
20210000944
2021-01-07

Compositions, methods and kits for eliciting an immune response

 #509
20210000943
2021-01-07

Compositions, methods and kits for eliciting an immune response

 #510
20200407728
2020-12-31

Altering Gene Expression in CART Cells and Uses Thereof

 #511
20200405764
2020-12-31

Materials and methods for engineering cells and uses thereof in immuno-oncology

 #512
20200405761
2020-12-31

Materials and methods for engineering cells and uses thereof in immuno-oncology

 #513
20200400676
2020-12-24

Articles and methods directed to personalized therapy of cancer

 #514
20200399597
2020-12-24

T-CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS

 #515
20200399393
2020-12-24

Dimeric antigen receptors

 #516
20200399320
2020-12-24

Chimeric polypeptides and uses thereof

 #517
20200392458
2020-12-17

MODIFIED NATURAL KILLER CELLS AND NATURAL KILLER CELL LINES TARGETTING TUMOUR CELLS

 #518
20200392248
2020-12-17

CD19-based chimeric antigen receptor and application thereof

 #519
20200392200
2020-12-17

Compositions and methods for treating cancer with DuoCARs

 #520
20200390814
2020-12-17

DNA-CHIMERIC ANTIGEN RECEPTOR T CELLS FOR IMMUNOTHERAPY

 #521
20200390811
2020-12-17

COMPOSITIONS TO DISRUPT PROTEIN KINASE A ANCHORING AND USES THEREOF

 #522
20200385677
2020-12-10

T-cell receptor-deficient T cell compositions

 #523
20200385474
2020-12-10

Antibody

 #524
20200368268
2020-11-26

IMMUNE-ENHANCING RNAS FOR COMBINATION WITH CHIMERIC ANTIGEN RECEPTOR THERAPY

 #525
20200363420
2020-11-19

ARTICLES AND METHODS DIRECTED TO PERSONALIZED THERAPY OF CANCER

 #526
20200360438
2020-11-19

Enhancing the effect of CAR-engineered T cells by means of nucleic acid vaccination

 #527
20200360433
2020-11-19

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #528
20200353004
2020-11-12

Regulatory T cell expressing a chimeric antigen receptor

 #529
20200345837
2020-11-05

Compositions, methods and kits for eliciting an immune response

 #530
20200339951
2020-10-29

T cell receptor-deficient t cell compositions

 #531
20200339950
2020-10-29

T cell receptor-deficient T cell compositions

 #532
20200339946
2020-10-29

Engineered multi-component system for identification and characterisation of T-cell receptors and T-cell antigens

 #533
20200338177
2020-10-29

Chimeric antigen receptors that bind to SSEA4 and uses thereof

 #534
20200332293
2020-10-22

ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN OR PEPTIDE EXPRESSION

 #535
20200332256
2020-10-22

Methods, kits, and compositions for enhancing cellular therapy

 #536
20200330572
2020-10-22

BCMA chimeric antigen receptors

 #537
20200330518
2020-10-22

Materials and methods for engineering cells and uses thereof in immuno-oncology

 #538
20200323919
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #539
20200323918
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #540
20200323916
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #541
20200323915
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #542
20200323914
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #543
20200323913
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #544
20200323911
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #545
20200323910
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #546
20200323909
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #547
20200323907
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #548
20200323906
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #549
20200318070
2020-10-08

ENGINEERED CELLS FOR ADOPTIVE CELL THERAPY

 #550
20200317782
2020-10-08

Protein-based T-cell receptor knockdown

 #551
20200317781
2020-10-08

Compositions and methods for immunotherapy

 #552
20200317764
2020-10-08

MODIFIED MRNA FOR MULTICELL TRANSFORMATION

 #553
20200306312
2020-10-01

Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer

 #554
20200306311
2020-10-01

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #555
20200306308
2020-10-01

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #556
20200306305
2020-10-01

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #557
20200297772
2020-09-24

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #558
20200297771
2020-09-24

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #559
20200297770
2020-09-24

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #560
20200283729
2020-09-10

TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR

 #561
20200283538
2020-09-10

Targeted protein degradation

 #562
20200283522
2020-09-10

M971 chimeric antigen receptors

 #563
20200281975
2020-09-10

Methods and compositions for gene editing in hematopoietic stem cells

 #564
20200271657
2020-08-27

ARTICLES AND METHODS DIRECTED TO PERSONALIZED THERAPY OF CANCER

 #565
20200270341
2020-08-27

Compositions and methods for treating cancer

 #566
20200268862
2020-08-27

Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)

 #567
20200268800
2020-08-27

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #568
20200268799
2020-08-27

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #569
20200268798
2020-08-27

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #570
20200268794
2020-08-27

COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY

 #571
20200262894
2020-08-20

STREP-TAG SPECIFIC BINDING PROTEINS AND USES THEREOF

 #572
20200261506
2020-08-20

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #573
20200261505
2020-08-20

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #574
20200261504
2020-08-20

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #575
20200261499
2020-08-20

Universal platform for preparing an inhibitory chimeric antigen receptor (iCAR)

 #576
20200255519
2020-08-13

Antibody chemically induced dimerizer (AbCID) as molecular switches for regulating cellular therapies

 #577
20200255494
2020-08-13

Cell

 #578
20200254078
2020-08-13

Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)

 #579
20200247870
2020-08-06

Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof

 #580
20200246452
2020-08-06

Compositions, methods and kits for eliciting an immune response

 #581
20200237886
2020-07-30

Costimulation of chimeric antigen receptors by MYD88 and CD40 polypeptides

 #582
20200237825
2020-07-30

ENGINEERING AND DELIVERY OF THERAPEUTIC COMPOSITIONS OF FRESHLY ISOLATED CELLS

 #583
20200237820
2020-07-30

T cell receptors for immunotherapy

 #584
20200231648
2020-07-23

Compositions and methods for treating cancer with DuoCARs

 #585
20200222465
2020-07-16

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #586
20200216543
2020-07-09

Nucleic acid, chimeric antigen receptor expression plasmid, chimeric antigen receptor expressing cell, use thereof, and pharmaceutical composition for treating cancer

 #587
20200215171
2020-07-09

TREATMENT OF CANCER USING A CLL-1 CHIMERIC ANTIGEN RECEPTOR

 #588
20200206271
2020-07-02

Combinatorial cancer immunotherapy

 #589
20200206268
2020-07-02

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #590
20200206265
2020-07-02

Methods of preparing T cells for T cell therapy

 #591
20200197502
2020-06-25

INDUCED ACTIVATION IN DENDRITIC CELLS

 #592
20200197441
2020-06-25

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #593
20200197437
2020-06-25

Reversing the effects of the tumor microenvironment using chimeric cytokine receptors

 #594
20200188505
2020-06-18

Universal influenza vaccine

 #595
20200182880
2020-06-11

Cancer antigen targets and uses thereof

 #596
20200179454
2020-06-11

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #597
20200179453
2020-06-11

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #598
20200179447
2020-06-11

Autologous irradiated whole cell tumor vaccines lentivirally engineered to express CD80, IL-15 and IL-15 receptor alpha

 #599
20200171091
2020-06-04

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #600
20200164059
2020-05-28

Epstein Barr virus antibodies, vaccines, and uses of the same